Edwards Lifesciences Corporation $EW Shares Bought by Primecap Management Co. CA

Primecap Management Co. CA lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 49.9% during the 2nd quarter, Holdings Channel.com reports. The fund owned 3,446,891 shares of the medical research company’s stock after buying an additional 1,147,291 shares during the period. Primecap Management Co. CA’s holdings in Edwards Lifesciences were worth $269,581,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Parkside Financial Bank & Trust boosted its position in Edwards Lifesciences by 9.8% during the second quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after acquiring an additional 130 shares during the last quarter. Prosperity Consulting Group LLC increased its position in shares of Edwards Lifesciences by 3.2% during the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after acquiring an additional 132 shares during the last quarter. NewSquare Capital LLC grew its position in shares of Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares in the last quarter. Dakota Wealth Management increased its stake in shares of Edwards Lifesciences by 2.5% in the second quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company’s stock valued at $473,000 after purchasing an additional 146 shares during the period. Finally, LRI Investments LLC boosted its position in Edwards Lifesciences by 1.0% during the 2nd quarter. LRI Investments LLC now owns 14,971 shares of the medical research company’s stock worth $1,171,000 after acquiring an additional 147 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on EW. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Sanford C. Bernstein restated a “market perform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a report on Monday, November 3rd. Canaccord Genuity Group restated a “hold” rating and set a $84.00 price objective (up previously from $81.00) on shares of Edwards Lifesciences in a report on Monday, November 3rd. BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Tuesday, July 29th. Finally, Citigroup upped their price target on shares of Edwards Lifesciences from $95.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $91.39.

Edwards Lifesciences Trading Down 0.7%

Shares of EW opened at $84.13 on Wednesday. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.21. The firm has a market capitalization of $48.82 billion, a price-to-earnings ratio of 12.11, a P/E/G ratio of 3.97 and a beta of 1.03. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock’s 50-day moving average price is $78.37 and its 200 day moving average price is $77.88.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business’s revenue was up 14.7% on a year-over-year basis. During the same period last year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.